

Electronic Supplementary Information for

Synthesis, Physico-Chemical and Biological Properties of Amphiphilic Amino Acid Conjugates of Nitroxides

Grégory Durand,^{a,*} Fanny Choteau,^a Robert A. Prosak,^b Antal Rockenbauer,^c Frederick A. Villamena^{b,d,*} and Bernard Pucci^a

^aLaboratoire de Chimie BioOrganique et des Systèmes Moléculaires Vectoriels, Faculté des Sciences, Université d'Avignon et des Pays de Vaucluse, 33 Rue Louis Pasteur, 84000 Avignon, France

^bDepartment of Pharmacology, ^dCenter for Biomedical EPR Spectroscopy and Imaging, The Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210

^cChemical Research Center, Institute of Structural Chemistry, H-1025 Budapest, Pusztaszeri 59, Hungary

gregory.durand@univ-avignon.fr

frederick.villamena@osumc.edu

Table of contents		Pages
Material, general procedure and instrumentation for the synthesis, experimental procedures for 10, 11, 13 and 14 and material and general procedure for cell culturing		S2-S3
Figure S1	¹ H NMR Spectrum of 1 in CDCl ₃	S4
Figure S2	¹³ C NMR spectrum of 1 in CDCl ₃	S5
Figure S3	¹ H NMR spectrum of LAH (2) in CDCl ₃	S6
Figure S4	¹³ C NMR spectrum of LAH (2) in CDCl ₃	S7
Figure S5	DEPT 135 spectrum of LAH (2) in CDCl ₃	S8
Figure S6	¹ H NMR spectrum of 5 in CDCl ₃	S9
Figure S7	¹³ C NMR spectrum of 5 in CDCl ₃	S10
Figure S8	¹ H NMR spectrum of LLH (6) in CDCl ₃	S11
Figure S9	¹³ C NMR spectrum of LLH (6) in CDCl ₃	S12
Figure S10	DEPT 135 spectrum of LLH (6) in CDCl ₃	S13
Figure S11	MS spectrum of LAH (2)	S14
Figure S12	MS spectrum of O-acetylated LAH-4-AT (3)	S14
Figure S13	HRMS spectrum of LAH-4-AT (4)	S15
Figure S14	MS spectrum of LLH (6)	S15
Figure S15	MS spectrum of O-acetylated LLH-3-CP (7)	S16
Figure S16	MS spectrum of LLH-3-CP (8)	S16
Figure S17	MS spectrum of O-acetylated LAF-4-AT (10)	S17
Figure S18	HRMS spectrum of LAF-4-AT (11)	S17
Figure S19	MS spectrum of O-acetylated LLF-3-CP (13)	S18
Figure S20	HRMS spectrum of LLF-3-CP (14)	S18
Figure S21	Concentration dependence of the nitrogen coupling for the unconjugated nitroxides 4-AT and 3-CP	S19
Figure S22	Concentration dependence of the linewidth for the unconjugated nitroxides 4-AT and 3-CP	S19
Figure S23	EPR spectra of the non-clustered and clustered LAH-4-AT (4)	S20
Figure S24	EPR spectra of the non-clustered and clustered LAF-4-AT (11)	S20
Figure S25	Radical distributions of the non-clustered and clustered radicals as a function of concentrations	S21
Figure S26	Reduction and restoration of the nitroxide EPR signals by ascorbic acid and potassium ferricyanide	
Figure S27	Relative EPR signal intensities of extracellular nitroxides after 1 h and 24 h incubation in the presence and absence of BAEC	S22

Material, general procedure and instrumentation for the synthesis

Synthesis. All reagents were used as purchased from Sigma-Aldrich or Acros except for amino acids which were purchased from Iris Biotech. and 1*H*,1*H*,2*H*,2*H*-perfluorooctyl iodide which was from Elf Atochem and were used without further purification. All solvents were distilled and dried according to standard procedures. TLC analyses were performed on sheets precoated with silica gel 60F254 (Merck). Compound detection was achieved either by exposure to ultraviolet light (254 nm), by spraying with a 5% sulphuric acid solution in ethanol or 2% ninhydrin solution in ethanol and then heating at ~150°C. Flash chromatography purifications were carried out on Merck silica gel Gerduran Si 60 (40-63 µm). Size exclusion chromatography purifications were carried out on Sephadex LH20 resin (Amersham Biosciences). UV spectra were recorded on a Varian CARY 100. Melting points were measured on an Electrothermal IA9100 apparatus and have not been corrected. Optical rotations were measured at 25°C on a Perkin Elemer MC 241 polarimeter. The ¹H, ¹³C, ¹⁹F and DEPT NMR sequences were recorded on a Brüker AC-250 spectrometer and were performed at 250, 62.86 and 235 MHz for ¹H, ¹³C and ¹⁹F experiments, respectively. Chemical shifts are given in ppm relative to the solvent residual peak as a heteronuclear reference for ¹H and ¹³C. Abbreviations used for signal patterns are: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublet. Mass spectra were recorded on a Qstar Elite (Applied Biosystems SCIEX) for MS ESI+ experiments and on a 3200 Qtrap (Applied Biosystems SCIEX) for HR-MS ESI+ experiments.

Experimental procedures for 10, 11, 13 and 14

***N*-(2,3,4,6,2',3',4',6'-*O*-acetyl-lactobionyl)- β -(4-amidoTEMPO)-*L*-aspartyl-1*H*,1*H*,2*H*,2*H*-perfluorooctylamide (10).** At 0°C, compound **9**²³ (0.3 g, 2.48 10⁻⁴ mol) was dissolved in a TFA/CH₂Cl₂ 4:6 (v/v) mixture. After 2 h of being stirred, the solution was concentrated under vacuum to give the corresponding acid derivative as a white powder (0.252 g, 2.18 10⁻⁴ mol, 88%). The acid derivative (0.240 g, 2.08 10⁻⁴ mol), EDC (0.075 g, 3.91 10⁻⁴ mol), 4-AT (0.024 g, 4.24 10⁻⁴ mol) and a catalytic amount of HOBT were dissolved in dry CH₂Cl₂ with DIEA (pH = 8-9) under argon. The mixture was stirred for 28 h at room temperature and then the solvent was evaporated under vacuum. The crude mixture was purified by flash chromatography (EtOAc/cyclohexane 7:3 v/v) followed by size exclusion chromatography (CH₂Cl₂/MeOH 1:1 v/v) to give compound **10** (0.162 g, 1.24 10⁻⁴ mol, 60%) as an orange powder. *R*_f 0.56 (EtOAc). mp 66-67°C (decomposition). λ_{max} (CH₂Cl₂)/nm 229. MS (ESI+, *m/z*) 1308.4 [(M+H)⁺], 1325.4 [(M+NH₄)⁺], 1330.4 [(M+Na)⁺], 1346.4 [(M+K)⁺].

***N*-Lactobionyl- β -(4-amidoTEMPO)-*L*-aspartyl-1*H*,1*H*,2*H*,2*H*-perfluorooctylamide (11).** Compound **10** (0.150 g, 1.15 10⁻⁴ mol) was dissolved under argon in MeOH and a catalytic amount of sodium methoxide was added. The mixture was stirred for 4 h and HCl 1N was added dropwise to neutralize the solution. The solvent was evaporated under vacuum and the crude mixture was purified by size exclusion chromatography (MeOH) to give compound **11** (0.073 g, 9.89 10⁻⁵ mol, 86%) as an orange powder. *R*_f 0.55

(EtOAc/MeOH/H₂O 7:2:1 v/v/v). mp 78-79°C (decomposition). $[\alpha]_{25}^D +18.2$ (c 0.1 in MeOH). $\lambda_{\max}(\text{MeOH})/\text{nm}$ 229. HR-MS (ESI+, m/z) calcd for C₃₃H₄₉N₄O₁₄F₁₃ [(M+H)⁺]: 972.3032, found 972.3030.

***N*-(2,3,4,6,2',3',4',6'-O-acetyl-lactobionyl)-*N*^e-(carboxyproxyl)-L-Lysinyl-1*H*,1*H*,2*H*,2*H*-perfluorooctylamide (13).** At 0°C, compound **12**²³ (0.3 g, 2.30 10⁻⁴ mol) was dissolved in ethanol/acetic acid 99:1 (v/v) and 0.018 g of 10% Pd/C was portion wise added under stirring. The reaction mixture was submitted to a hydrogen atmosphere for 12 h (8 bars). After filtration of the catalyst through a pad of Celite, the solvent was evaporated under vacuum to give the corresponding amino derivative (0.263 g, 2.26 10⁻⁴ mol). The resulting amino (0.250 g, 2.14 10⁻⁴ mol), EDC (0.049 g, 2.57 10⁻³ mol), 3-CP (0.048 g, 2.57 10⁻³ mol) and a catalytic amount of HOBT were dissolved in dry CH₂Cl₂ with DIEA (pH = 8-9) under argon. The mixture was stirred for 18 h at room temperature and the solvent was evaporated under vacuum. The crude mixture was purified by flash chromatography (EtOAc) and by size exclusion chromatography (CH₂Cl₂/MeOH 1:1 v/v) to give compound **13** (0.082 g, 6.14 10⁻⁵ mol, 28%) as a yellow powder. *R*_f 0.58 (EtOAc). mp 82.6-83.8°C (decomposition). $[\alpha]_{25}^D +3.6$ (c 1 in CH₂Cl₂). $\lambda_{\max}(\text{CH}_2\text{Cl}_2)/\text{nm}$ 203. MS (ESI+, m/z) 1336.5 [(M+H)⁺], 1353.6 [(M+NH₄)⁺], 1358.5 [(M+Na)⁺], 1374.5 [(M+K)⁺], 1334.5 [(M-H)⁻]

***N*-lactobionyl-*N*^e-(carboxyproxyl)-L-Lysinyl-1*H*,1*H*,2*H*,2*H*-perfluorooctylamide (14).** Compound **13** (0.070g, 5.24 10⁻⁵ mol) was dissolved under argon in MeOH and a catalytic amount of sodium methoxide was added. The mixture was stirred for 4 h and HCl 1N was added dropwise to neutralize the solution. The solvent was evaporated under vacuum and the crude mixture was purified by size exclusion chromatography (MeOH), to give the compound **14** (0.046g, 4.6 10⁻⁵ mol, 88%) as a yellow powder. *R*_f 0.51 (EtOAc/MeOH/H₂O 7:2:1 v/v/v). mp 108.5-109.5°C (decomposition). $[\alpha]_{25}^D +11.3$ (c 0.1 in MeOH). $\lambda_{\max}(\text{MeOH})/\text{nm}$ 203. HR-MS (ESI+, m/z) calcd for C₃₅H₅₃N₄O₁₄F₁₃ [(M+H)⁺]: 1000.3345, found 1000.3353; calcd for C₃₅H₅₆N₅O₁₄F₁₃ [(M+NH₄)⁺]: 1017.3611, found 1017.3621.

Material and general procedure for cell culturing

All reagents or materials were purchased and used without further purification. Bovine aortic endothelial cells (BAEC) were purchased from Cell Systems (Kirkland, WA). Cells were cultured in 75 cm² tissue culture flasks using Dulbecco's modified eagle medium with 4.5 g/L D-glucose and supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 2.5 mg/L endothelial cell growth supplement, and 1% non-essential amino acids (Gibco) in the absence of antibiotics at 37°C in a humidified atmosphere of 5% CO₂ and 20% O₂. The medium was changed every 2-3 days and cells were sub-cultured once they reached 90–95% confluence.




Figure S1. ¹H NMR Spectrum of **1** in CDCl₃




Figure S2. ^{13}C NMR spectrum of **1** in CDCl_3




Figure S3. ^1H NMR spectrum of LAH (2) in CDCl_3




Figure S4. ^{13}C NMR spectrum of LAH (2) in CDCl_3




Figure S5. DEPT 135 spectrum of LAH (2) in CDCl₃




Figure S6. ¹H NMR spectrum of **5** in CDCl₃




Figure S7. ^{13}C NMR spectrum of **5** in CDCl_3




Figure S8. ¹H NMR spectrum of LLH (6) in CDCl₃




Figure S9. ^{13}C NMR spectrum of LLH (6) in CDCl_3




Figure S10. DEPT 135 spectrum of LLH (6) in CDCl₃




Figure S11. MS spectrum of LAH (2)




Figure S12. MS spectrum of O-acetylated LAH-4-AT (3)




Figure S13. HRMS spectrum of LAH-4-AT (4)




Figure S14. MS spectrum of LLH (6)




Figure S15. MS spectrum of O-acetylated LLH-3-CP (7)




Figure S16. MS spectrum of LLH-3-CP (8)




Figure S17. MS spectrum of O-acetylated LAF-4-AT (**10**)




Figure S18. HRMS spectrum of LAF-4-AT (**11**)




Figure S19. MS spectrum of O-acetylated LLF-3-CP (**13**)




Figure S20. HRMS spectrum of LLF-3-CP (**14**)




Figure S21. Concentration dependence of the nitrogen coupling for the unconjugated nitroxides.




Figure S22. Concentration dependence of the linewidth for the unconjugated nitroxides.




Figure S23. EPR spectra of the non-clustered and clustered LAH-4-AT (**4**)




Figure S24. EPR spectra of the non-clustered and clustered LAF-4-AT (**11**)




Figure S25. Radical distributions of the non-clustered and clustered radicals as a function of concentrations.




Figure S26. Reduction and restoration of the nitroxide EPR signals by ascorbic acid and potassium ferricyanide. 25 μM of nitroxide was measured by EPR (see experimental for details) over a 30 min period and the signal intensity was found to be stable. 250 μM ascorbic acid was added and the EPR spectra were taken again for 30 min. 250 μM $\text{K}_3[\text{Fe}(\text{CN})_6]$ was then added to the sample with ascorbic acid and the EPR spectra was taken again for another 30 min. The y-axis corresponds to the relative intensity compared to the 25 μM of nitroxide. $n=2$.




Figure S27. Relative EPR signal intensities of extracellular nitroxides after 1 h and 24 h incubation in the presence and absence of BAEC. EPR spectra were again taken after addition of 250 μM K₃[Fe(CN)₆]. Plots are relative to the signal intensity of 25 μM nitroxide in DMEM normalized to 100%. In this figure is also shown the result of lysed cells one hour after being incubated with 4-AT. An EPR signal consistent with the presence of 4-AT compound was observed with a relative intensity of 7.5% while the extracellular concentration is about 50%.